In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS ...
PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market LaunchFDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale UpMPAR® Patent Protection Extended Through ...
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback